Vericel (NASDAQ: VCEL)
Vericel Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Vericel Company Info
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
News & Analysis
Why Vericel Tumbled by Nearly 15% on Tuesday
The FDA says "no" to the company's NexoBrid -- for now.
Why Vericel Stock Raced 13% Higher on Thursday
The company will be a component of a well-known small-cap stock index.
2 Overvalued Biotech Stocks Still Worth Buying
Sometimes valuation metrics can be deceiving.
Why Vericel Stock Is Soaring Today
Shares jumped in response to upbeat third-quarter results and a guidance boost.
Why Vericel Jumped Higher Today
It was a solid fourth quarter for the biotech, with more revenue growth expected in 2018.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.